ArticleCureus2024
Vasant Kusumakar Rasa Ameliorates Diabetic Encephalopathy by Reducing Oxidative Stress and Neuroinflammation and Improving Neurotransmitter Levels in Experimental Animals.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Icariin Ameliorates Cyclophosphamide-Induced Renal Encephalopathy by Modulating the NF-κB and Keap1-Nrf2 Signaling Pathways.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDiabetic encephalopathy (DE) is one of the complications of diabetes that affects the brain. In the Ayurveda system of medicine, Vasant Kusumakar Rasa (VKR) is cited as a classical herbo-mineral formulation for diabetes. However, the role of VKR in DE is still unclear.
methodsHigh-fat diet and streptozotocin (35 mg/kg,
resultsVKR treatment, at a dose of 28 and 56 mg/kg, reduced the plasma glucose level significantly (236.7±17.08 and 221.8±17.50, respectively; p<0.001) when compared with diabetic control (461.7±13.03). The treatment also reduced serum insulin and glycated hemoglobin levels and improved the escape latency in VKR-treated animals as compared to diabetic animals. Brain tissue pro-inflammatory marker levels were reduced, and oxidative stress enzymes showed positive marks in diabetic rats treated with VKR. Histopathology of the brain demonstrated a reduction in neuronal damage in the VKR-treated diabetic animals. VKR treatment at doses of 28 and 56 mg/kg also improved the levels of 5-HT (1.78±0.11 and 1.72±0.18, respectively) when compared with diabetic control (0.91±0.08) significantly (p<0.01). DA levels were significantly (p<0.01) increased in VKR-treated animals when compared with diabetic animals. The treatment of VKR for 16 weeks also improved the NE levels significantly when compared with diabetic control animals.
conclusionThe result of the study indicates that the treatment with VKR for 16 weeks has significant therapeutic potential in the management of type 2 DE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.